Sovaldi, a direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV), had an average wholesale acquisition cost (WAC) of $1,000 per day in 2013, or $84,000 for a 12-week course of treatment. Sovaldi’s launch kicked off the second generation of DAAs for HCV, which expanded more widely tolerable treatment options to patients, including increased potential toward HCV elimination for the first time. This report discusses the reduction in cost per treatment regimen to an average net cost of approximately $11,500 to $17,000 in mid-2020.

This report was commissioned by Gilead Sciences, Inc.